Callisto Pharmaceuticals, Inc. (OTC BB: CLSP) announced that Dr. Robert Kyle, Professor of Medicine and Laboratory Medicine at the Mayo Clinic in Rochester, Minnesota, has been appointed Chairman of Callisto’s Scientific Advisory Board. Dr. Kyle is an expert in the field of hematological cancers, with a special interest in the biology and management of multiple myeloma, amyloidosis and similar blood disorders.
Formerly Chairman of the Division of Hematology at the Mayo Clinic, Dr. Kyle serves on the Scientific Boards of a number of foundations and societies devoted to myeloma and hematological diseases, and is the recipient of numerous awards and honors including the Waldenstrom Award for Myeloma Research, Henry S. Plummer Distinguished Internist Award, and the Distinguished Clinician Award from Mayo Clinic.
” We are delighted to have Dr. Kyle as the Chairman of the Scientific Advisory Board,” said Dr. Gary S. Jacob, CEO of Callisto Pharmaceuticals, Inc. “Dr. Kyle has devoted his life to exploring blood cancers and to the treatment of these and similar conditions. His vast knowledge will be of considerable value as we move our drug candidate for multiple myeloma, Atiprimod, forward into the clinic.” About Callisto Pharmaceuticals, Inc.
Callisto is a biopharmaceutical company primarily focused on the development of drugs to treat multiple myeloma, other cancers and osteolytic bone disease. Callisto’s lead drug candidate, Atiprimod, is a small-molecule, orally available drug with antiproliferative and antiangiogenic activity. Atiprimod successfully completed Phase I clinical trials in rheumatoid arthritis patients and Callisto plans to enter Atiprimod in a safety and proof-of-principle clinical trial in multiple myeloma patients. The drug is also being explored as an agent to treat osteolytic bone disease. In addition, Callisto has programs focused on the development of an analog of the human intestinal hormone, uroguanylin, to treat colon cancer, and drugs to protect against staphylococcal and streptococcal bioweapons, protecting against the devastating effects of toxic shock syndrome. Callisto has two operating subsidiaries, Callisto Research Labs, LLC and Synergy Pharmaceuticals Inc. Callisto has an exclusive worldwide license from AnorMED Inc. to develop, manufacture, use and sell Atiprimod. For additional information, visit www.callistopharma.com.
Included in this release are “forward-looking” statements. Such statements are indicated by words such as “expect,” “should,” “anticipate” and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. Callisto’s actual results could differ materially from those anticipated in the forward-looking statements as a result of various factors.